Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 14/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | PKM | P14618 | 1/20 | 0.47 |
| ▸ | FAAH | O00519 | 1/20 | 0.45 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.44 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.44 |
| ▸ | GLS | O94925 | 1/20 | 0.44 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL389040 | 0.83 | GPR119 (0.47) | GPR119KDM4EPKMFAAHKEAP1 | |
| SCHEMBL389041 | 0.83 | GPR119 (0.47) | GPR119KDM4EPKMFAAHKEAP1 | |
| SCHEMBL389345 | 0.82 | GPR119 (0.48) | GPR119KDM4EPKMFAAHKEAP1 | |
| SCHEMBL386513 | 0.82 | GPR119 (0.48) | GPR119KDM4EPKMFAAHKEAP1 | |
| SCHEMBL386514 | 0.82 | GPR119 (0.48) | GPR119KDM4EPKMFAAHKEAP1 | |
| SCHEMBL390265 | 0.81 | GPR119 (0.49) | GPR119KDM4EPKMFAAHKEAP1 | |
| SCHEMBL390097 | 0.81 | GPR119 (0.49) | GPR119KDM4EPKMFAAHKEAP1 | |
| SCHEMBL390096 | 0.81 | GPR119 (0.49) | GPR119KDM4EPKMFAAHKEAP1 | |
| SCHEMBL5257521 | 0.79 | GPR119 (0.50) | GPR119KDM4EPKMFAAHKEAP1 | |
| SCHEMBL5254511 | 0.79 | GPR119 (0.46) | GPR119KDM4EPKMFAAHKEAP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080312281-A1 | G-Protein Coupled Receptor (Gpr116) Agonists and Use Thereof for Treating Obesity and Diabetes | PROSIDION LIMITED (GB) | 2008-12-18 | — | — | US | disclosed |
| EP-1838311-A1 | G-PROTEIN COUPLED RECEPTOR (GPR116) AGONISTS AND USE THEREOF FOR TREATING OBESITY AND DIABETES | Prosidion Limited (GB) | 2007-10-03 | — | — | EP | disclosed |
| WO-2006067531-A1 | G-PROTEIN COUPLED RECEPTOR (GPR116) AGONISTS AND USE THEREOF FOR TREATING OBESITY AND DIABETES | PROSIDION LTD (GB) | 2006-06-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080312281-A1 | G-Protein Coupled Receptor (Gpr116) Agonists and Use Thereof for Treating Obesity and Diabetes | GPR119, GCGR, GPR65 | GPR119 1/4885KDM4E 4397/4885PKM 3076/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.